المؤلفون: Xie O., Rogers B., Hughes C., Taylor L., Cisera K.

مصطلحات الفهرس: major clinical study, male, nonhuman, outpatient care, prediction, retrospective study, treatment contraindication, treatment indication, amikacin/dt [Drug Therapy], amikacin/pv [Special Situation for Pharmacovigilance], avibactam plus ceftazidime/dt [Drug Therapy], avibactam plus ceftazidime/pv [Special Situation for Pharmacovigilance], carbapenem/dt [Drug Therapy], carbapenem/pv [Special Situation for Pharmacovigilance], cefiderocol/dt [Drug Therapy], cefiderocol/pv [Special Situation for Pharmacovigilance], ceftazidime/dt [Drug Therapy], ceftazidime/pv [Special Situation for Pharmacovigilance], ceftolozane plus tazobactam/dt [Drug Therapy], ceftolozane plus tazobactam/pv [Special Situation for Pharmacovigilance], ceftriaxone/dt [Drug Therapy], ceftriaxone/pv [Special Situation for Pharmacovigilance], ciprofloxacin/dt [Drug Therapy], ciprofloxacin/pv [Special Situation for Pharmacovigilance], cotrimoxazole/dt [Drug Therapy], cotrimoxazole/pv [Special Situation for Pharmacovigilance], ertapenem/dt [Drug Therapy], ertapenem/pv [Special Situation for Pharmacovigilance], fosfomycin/dt [Drug Therapy], fosfomycin/iv [Intravenous Drug Administration], fosfomycin/pv [Special Situation for Pharmacovigilance], gentamicin/dt [Drug Therapy], gentamicin/pv [Special Situation for Pharmacovigilance], meropenem/dt [Drug Therapy], meropenem/pv [Special Situation for Pharmacovigilance], piperacillin plus tazobactam/dt [Drug Therapy], piperacillin plus tazobactam/pv [Special Situation for Pharmacovigilance], plazomicin/pv [Special Situation for Pharmacovigilance], tobramycin/dt [Drug Therapy], tobramycin/pv [Special Situation for Pharmacovigilance], mass spectrometer, microbial identification system, plazomicin/dt [Drug Therapy], adult, aged, antibiotic resistance, antibiotic sensitivity, antimicrobial therapy, article, bacteremia/dr [Drug Resistance], bacteremia/dt [Drug Therapy], bloodstream infection/dr [Drug Resistance], bloodstream infection/dt [Drug Therapy], clinical feature, cohort analysis, drug substitution, Escherichia coli, female, hospital patient, human, Article

URL: Annals of Clinical Microbiology and Antimicrobials
Click here for full text options
LibKey Link

المؤلفون: Xie O., Rogers B., Hughes C., Taylor L., Cisera K.

مصطلحات الفهرس: major clinical study, male, nonhuman, outpatient care, prediction, retrospective study, treatment contraindication, treatment indication, amikacin/dt [Drug Therapy], amikacin/pv [Special Situation for Pharmacovigilance], avibactam plus ceftazidime/dt [Drug Therapy], avibactam plus ceftazidime/pv [Special Situation for Pharmacovigilance], carbapenem/dt [Drug Therapy], carbapenem/pv [Special Situation for Pharmacovigilance], cefiderocol/dt [Drug Therapy], cefiderocol/pv [Special Situation for Pharmacovigilance], ceftazidime/dt [Drug Therapy], ceftazidime/pv [Special Situation for Pharmacovigilance], ceftolozane plus tazobactam/dt [Drug Therapy], ceftolozane plus tazobactam/pv [Special Situation for Pharmacovigilance], ceftriaxone/dt [Drug Therapy], ceftriaxone/pv [Special Situation for Pharmacovigilance], ciprofloxacin/dt [Drug Therapy], ciprofloxacin/pv [Special Situation for Pharmacovigilance], cotrimoxazole/dt [Drug Therapy], cotrimoxazole/pv [Special Situation for Pharmacovigilance], ertapenem/dt [Drug Therapy], ertapenem/pv [Special Situation for Pharmacovigilance], fosfomycin/dt [Drug Therapy], fosfomycin/iv [Intravenous Drug Administration], fosfomycin/pv [Special Situation for Pharmacovigilance], gentamicin/dt [Drug Therapy], gentamicin/pv [Special Situation for Pharmacovigilance], meropenem/dt [Drug Therapy], meropenem/pv [Special Situation for Pharmacovigilance], piperacillin plus tazobactam/dt [Drug Therapy], piperacillin plus tazobactam/pv [Special Situation for Pharmacovigilance], plazomicin/pv [Special Situation for Pharmacovigilance], tobramycin/dt [Drug Therapy], tobramycin/pv [Special Situation for Pharmacovigilance], mass spectrometer, microbial identification system, plazomicin/dt [Drug Therapy], adult, aged, antibiotic resistance, antibiotic sensitivity, antimicrobial therapy, article, bacteremia/dr [Drug Resistance], bacteremia/dt [Drug Therapy], bloodstream infection/dr [Drug Resistance], bloodstream infection/dt [Drug Therapy], clinical feature, cohort analysis, drug substitution, Escherichia coli, female, hospital patient, human, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/28970
Annals of Clinical Microbiology and Antimicrobials
LibKey Link

المؤلفون: Harris P., Rogers B., Paterson D.

مصطلحات الفهرس: human, infection risk, Klebsiella pneumoniae, multidrug resistance, note, Pseudomonas aeruginosa, risk assessment, amikacin/dt [Drug Therapy], aminoglycoside derivative/dt [Drug Therapy], amoxicillin/dt [Drug Therapy], beta lactam antibiotic/dt [Drug Therapy], carbapenem derivative/dt [Drug Therapy], cefotaxime/dt [Drug Therapy], ceftriaxone/dt [Drug Therapy], cephalosporin derivative/dt [Drug Therapy], clavulanic acid/dt [Drug Therapy], colistin/dt [Drug Therapy], fosfomycin/dt [Drug Therapy], monobactam derivative/dt [Drug Therapy], nitrofurantoin/dt [Drug Therapy], penicillin derivative/dt [Drug Therapy], piperacillin/dt [Drug Therapy], quinoline derived antiinfective agent/dt [Drug Therapy], tazobactam/dt [Drug Therapy], tigecycline/dt [Drug Therapy], cephalosporin resistant enterobacteriaceae, clinical decision making, Acinetobacter baumannii, antibiotic resistance, Australia, bacterial infection/dr [Drug Resistance], bacterial infection/dt [Drug Therapy], carbapenem-resistant Enterobacteriaceae, community acquired infection, disease transmission, Enterobacteriaceae, Escherichia coli, Gram negative bacterium, hospital infection, Note

URL: Medical Journal of Australia
Click here for full text options
LibKey Link

المؤلفون: Harris P., Rogers B., Paterson D.

مصطلحات الفهرس: human, infection risk, Klebsiella pneumoniae, multidrug resistance, note, Pseudomonas aeruginosa, risk assessment, amikacin/dt [Drug Therapy], aminoglycoside derivative/dt [Drug Therapy], amoxicillin/dt [Drug Therapy], beta lactam antibiotic/dt [Drug Therapy], carbapenem derivative/dt [Drug Therapy], cefotaxime/dt [Drug Therapy], ceftriaxone/dt [Drug Therapy], cephalosporin derivative/dt [Drug Therapy], clavulanic acid/dt [Drug Therapy], colistin/dt [Drug Therapy], fosfomycin/dt [Drug Therapy], monobactam derivative/dt [Drug Therapy], nitrofurantoin/dt [Drug Therapy], penicillin derivative/dt [Drug Therapy], piperacillin/dt [Drug Therapy], quinoline derived antiinfective agent/dt [Drug Therapy], tazobactam/dt [Drug Therapy], tigecycline/dt [Drug Therapy], cephalosporin resistant enterobacteriaceae, clinical decision making, Acinetobacter baumannii, antibiotic resistance, Australia, bacterial infection/dr [Drug Resistance], bacterial infection/dt [Drug Therapy], carbapenem-resistant Enterobacteriaceae, community acquired infection, disease transmission, Enterobacteriaceae, Escherichia coli, Gram negative bacterium, hospital infection, Note

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/40803
Medical Journal of Australia
LibKey Link

المؤلفون: Holmes P.W., King P.T.

مصطلحات الفهرس: maintenance therapy, multiple cycle treatment, priority journal, QT prolongation/si [Side Effect], randomized controlled trial (topic), respiratory tract infection, review, treatment response, amoxicillin/ct [Clinical Trial], amoxicillin/dt [Drug Therapy], amoxicillin/po [Oral Drug Administration], antibiotic agent/ct [Clinical Trial], antibiotic agent/dt [Drug Therapy], antibiotic agent/ih [Inhalational Drug Administration], azithromycin/ae [Adverse Drug Reaction], azithromycin/dt [Drug Therapy], ceftazidime/ct [Clinical Trial], ceftazidime/dt [Drug Therapy], ceftazidime/ih [Inhalational Drug Administration], ciprofloxacin/ct [Clinical Trial], ciprofloxacin/dt [Drug Therapy], ciprofloxacin/ih [Inhalational Drug Administration], clarithromycin/dt [Drug Therapy], colistin/ct [Clinical Trial], colistin/cb [Drug Combination], colistin/dt [Drug Therapy], colistin/ih [Inhalational Drug Administration], erythromycin/ae [Adverse Drug Reaction], erythromycin/dt [Drug Therapy], fosfomycin/ct [Clinical Trial], fosfomycin/dt [Drug Therapy], fosfomycin/tr [Intratracheal Drug Administration], gentamicin/ct [Clinical Trial], gentamicin/dt [Drug Therapy], gentamicin/ih [Inhalational Drug Administration], macrolide/ct [Clinical Trial], macrolide/dt [Drug Therapy], ofloxacin/ct [Clinical Trial], ofloxacin/dt [Drug Therapy], quinolone derivative/ct [Clinical Trial], quinolone derivative/cb [Drug Combination], quinolone derivative/dt [Drug Therapy], roxithromycin/dt [Drug Therapy], tobramycin/ct [Clinical Trial], tobramycin/dt [Drug Therapy], tobramycin/tr [Intratracheal Drug Administration], ofloxacin/po [Oral Drug Administration], antibiotic resistance, antibiotic therapy, bronchiectasis/dt [Drug Therapy], bronchiectasis/co [Complication], bronchiectasis/dr [Drug Resistance], bronchiectasis/et [Etiology], disease exacerbation, drug efficacy, drug tolerability, gastrointestinal symptom/si [Side Effect], human, long term care, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/28255
Click here for full text options
LibKey Link

المؤلفون: Turnidge J., Grayson M.L.

مصطلحات الفهرس: drug potency, drug protein binding, gastrointestinal symptom/si [Side Effect], Gram negative bacterium, hospital infection, human, interstitial nephritis/si [Side Effect], intravenous drug administration, lung infection/dt [Drug Therapy], nephrotoxicity/si [Side Effect], oral drug administration, osteomyelitis/dt [Drug Therapy], penicillin resistance, pharmacokinetics, review, sepsis/dt [Drug Therapy], skin infection/dt [Drug Therapy], Staphylococcus aureus, Staphylococcus infection/dt [Drug Therapy], toxic shock syndrome/dt [Drug Therapy], aminoglycoside antibiotic agent/dt [Drug Therapy], amoxicillin/cb [Drug Combination], amoxicillin/dt [Drug Therapy], ampicillin/cb [Drug Combination], ampicillin/dt [Drug Therapy], azithromycin/dt [Drug Therapy], beta lactam/cb [Drug Combination], beta lactam/dt [Drug Therapy], beta lactamase/ec [Endogenous Compound], cefaclor/dt [Drug Therapy], cefadroxil/dt [Drug Therapy], cefalexin/dt [Drug Therapy], cefaloridine/dt [Drug Therapy], cefalotin/dt [Drug Therapy], cefamandole/dt [Drug Therapy], cefapirin/dt [Drug Therapy], cefazolin/dt [Drug Therapy], cefradine/dt [Drug Therapy], cefuroxime/dt [Drug Therapy], cephalosporin/dt [Drug Therapy], chloramphenicol/dt [Drug Therapy], ciprofloxacin/dt [Drug Therapy], clarithromycin/dt [Drug Therapy], clavulanic acid/cb [Drug Combination], clavulanic acid/dt [Drug Therapy], clindamycin/dt [Drug Therapy], cloxacillin/dt [Drug Therapy], cotrimoxazole/cb [Drug Combination], cotrimoxazole/dt [Drug Therapy], dicloxacillin/dt [Drug Therapy], enoxacin/dt [Drug Therapy], enzyme inhibitor, erythromycin/dt [Drug Therapy], flucloxacillin/ae [Adverse Drug Reaction], flucloxacillin/dt [Drug Therapy], fosfomycin/dt [Drug Therapy], fusidic acid/dt [Drug Therapy], imipenem/dt [Drug Therapy], lincomycin/dt [Drug Therapy], meticillin/ae [Adverse Drug Reaction], meticillin/dt [Drug Therapy], minocycline/dt [Drug Therapy], nafcillin/dt [Drug Therapy], ofloxacin/dt [Drug Therapy], oxacillin/dt [Drug Therapy], pefloxacin/dt [Drug Therapy], penicillin G/dt [Drug Therapy], penicillinase/cb [Drug Combination], penicillinase/dt [Drug Therapy], piperacillin/cb [Drug Combination], piperacillin/dt [Drug Therapy], quinoline derived antiinfective agent/dt [Drug Therapy], rifampicin/dt [Drug Therapy], roxithromycin/dt [Drug Therapy], sulbactam/cb [Drug Combination], sulbactam/dt [Drug Therapy], sulfamethoxazole/cb [Drug Combination], sulfamethoxazole/dt [Drug Therapy], tazobactam/cb [Drug Combination], tazobactam/dt [Drug Therapy], teicoplanin/dt [Drug Therapy], temafloxacin/dt [Drug Therapy], tetracycline/dt [Drug Therapy], ticarcillin/cb [Drug Combination], ticarcillin/dt [Drug Therapy], trimethoprim/cb [Drug Combination], trimethoprim/dt [Drug Therapy], vancomycin/dt [Drug Therapy], priority journal, abscess/dt [Drug Therapy], allergy/si [Side Effect], anaphylaxis/si [Side Effect], antibiotic resistance, antibiotic therapy, antimicrobial therapy, aplastic anemia/si [Side Effect], bacteremia/et [Etiology], bacterial endocarditis/dt [Drug Therapy], bacterial meningitis/dt [Drug Therapy], cholestasis/si [Side Effect], coagulase negative Staphylococcus, drug efficacy, drug mixture, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/34435
Click here for full text options
LibKey Link

المؤلفون: Holmes P.W., King P.T.

مصطلحات الفهرس: maintenance therapy, multiple cycle treatment, priority journal, QT prolongation/si [Side Effect], randomized controlled trial (topic), respiratory tract infection, review, treatment response, amoxicillin/ct [Clinical Trial], amoxicillin/dt [Drug Therapy], amoxicillin/po [Oral Drug Administration], antibiotic agent/ct [Clinical Trial], antibiotic agent/dt [Drug Therapy], antibiotic agent/ih [Inhalational Drug Administration], azithromycin/ae [Adverse Drug Reaction], azithromycin/dt [Drug Therapy], ceftazidime/ct [Clinical Trial], ceftazidime/dt [Drug Therapy], ceftazidime/ih [Inhalational Drug Administration], ciprofloxacin/ct [Clinical Trial], ciprofloxacin/dt [Drug Therapy], ciprofloxacin/ih [Inhalational Drug Administration], clarithromycin/dt [Drug Therapy], colistin/ct [Clinical Trial], colistin/cb [Drug Combination], colistin/dt [Drug Therapy], colistin/ih [Inhalational Drug Administration], erythromycin/ae [Adverse Drug Reaction], erythromycin/dt [Drug Therapy], fosfomycin/ct [Clinical Trial], fosfomycin/dt [Drug Therapy], fosfomycin/tr [Intratracheal Drug Administration], gentamicin/ct [Clinical Trial], gentamicin/dt [Drug Therapy], gentamicin/ih [Inhalational Drug Administration], macrolide/ct [Clinical Trial], macrolide/dt [Drug Therapy], ofloxacin/ct [Clinical Trial], ofloxacin/dt [Drug Therapy], quinolone derivative/ct [Clinical Trial], quinolone derivative/cb [Drug Combination], quinolone derivative/dt [Drug Therapy], roxithromycin/dt [Drug Therapy], tobramycin/ct [Clinical Trial], tobramycin/dt [Drug Therapy], tobramycin/tr [Intratracheal Drug Administration], ofloxacin/po [Oral Drug Administration], antibiotic resistance, antibiotic therapy, bronchiectasis/dt [Drug Therapy], bronchiectasis/co [Complication], bronchiectasis/dr [Drug Resistance], bronchiectasis/et [Etiology], disease exacerbation, drug efficacy, drug tolerability, gastrointestinal symptom/si [Side Effect], human, long term care, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/28255
LibKey Link

المؤلفون: Turnidge J., Grayson M.L.

مصطلحات الفهرس: drug potency, drug protein binding, gastrointestinal symptom/si [Side Effect], Gram negative bacterium, hospital infection, human, interstitial nephritis/si [Side Effect], intravenous drug administration, lung infection/dt [Drug Therapy], nephrotoxicity/si [Side Effect], oral drug administration, osteomyelitis/dt [Drug Therapy], penicillin resistance, pharmacokinetics, review, sepsis/dt [Drug Therapy], skin infection/dt [Drug Therapy], Staphylococcus aureus, Staphylococcus infection/dt [Drug Therapy], toxic shock syndrome/dt [Drug Therapy], aminoglycoside antibiotic agent/dt [Drug Therapy], amoxicillin/cb [Drug Combination], amoxicillin/dt [Drug Therapy], ampicillin/cb [Drug Combination], ampicillin/dt [Drug Therapy], azithromycin/dt [Drug Therapy], beta lactam/cb [Drug Combination], beta lactam/dt [Drug Therapy], beta lactamase/ec [Endogenous Compound], cefaclor/dt [Drug Therapy], cefadroxil/dt [Drug Therapy], cefalexin/dt [Drug Therapy], cefaloridine/dt [Drug Therapy], cefalotin/dt [Drug Therapy], cefamandole/dt [Drug Therapy], cefapirin/dt [Drug Therapy], cefazolin/dt [Drug Therapy], cefradine/dt [Drug Therapy], cefuroxime/dt [Drug Therapy], cephalosporin/dt [Drug Therapy], chloramphenicol/dt [Drug Therapy], ciprofloxacin/dt [Drug Therapy], clarithromycin/dt [Drug Therapy], clavulanic acid/cb [Drug Combination], clavulanic acid/dt [Drug Therapy], clindamycin/dt [Drug Therapy], cloxacillin/dt [Drug Therapy], cotrimoxazole/cb [Drug Combination], cotrimoxazole/dt [Drug Therapy], dicloxacillin/dt [Drug Therapy], enoxacin/dt [Drug Therapy], enzyme inhibitor, erythromycin/dt [Drug Therapy], flucloxacillin/ae [Adverse Drug Reaction], flucloxacillin/dt [Drug Therapy], fosfomycin/dt [Drug Therapy], fusidic acid/dt [Drug Therapy], imipenem/dt [Drug Therapy], lincomycin/dt [Drug Therapy], meticillin/ae [Adverse Drug Reaction], meticillin/dt [Drug Therapy], minocycline/dt [Drug Therapy], nafcillin/dt [Drug Therapy], ofloxacin/dt [Drug Therapy], oxacillin/dt [Drug Therapy], pefloxacin/dt [Drug Therapy], penicillin G/dt [Drug Therapy], penicillinase/cb [Drug Combination], penicillinase/dt [Drug Therapy], piperacillin/cb [Drug Combination], piperacillin/dt [Drug Therapy], quinoline derived antiinfective agent/dt [Drug Therapy], rifampicin/dt [Drug Therapy], roxithromycin/dt [Drug Therapy], sulbactam/cb [Drug Combination], sulbactam/dt [Drug Therapy], sulfamethoxazole/cb [Drug Combination], sulfamethoxazole/dt [Drug Therapy], tazobactam/cb [Drug Combination], tazobactam/dt [Drug Therapy], teicoplanin/dt [Drug Therapy], temafloxacin/dt [Drug Therapy], tetracycline/dt [Drug Therapy], ticarcillin/cb [Drug Combination], ticarcillin/dt [Drug Therapy], trimethoprim/cb [Drug Combination], trimethoprim/dt [Drug Therapy], vancomycin/dt [Drug Therapy], priority journal, abscess/dt [Drug Therapy], allergy/si [Side Effect], anaphylaxis/si [Side Effect], antibiotic resistance, antibiotic therapy, antimicrobial therapy, aplastic anemia/si [Side Effect], bacteremia/et [Etiology], bacterial endocarditis/dt [Drug Therapy], bacterial meningitis/dt [Drug Therapy], cholestasis/si [Side Effect], coagulase negative Staphylococcus, drug efficacy, drug mixture, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/34435
LibKey Link